Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD Inc. (NSPR) is a medical device company pioneering MicroNet stent technology for stroke prevention through advanced carotid artery treatments. This page serves as the definitive source for verified corporate announcements, clinical developments, and strategic updates.
Investors and medical professionals will discover timely updates including FDA regulatory progress, international clinical trial results, product launch details, and partnership announcements. All content undergoes rigorous verification to ensure accuracy and relevance to stakeholder decision-making.
The resource features critical developments in vascular intervention technology, including innovations in embolic protection systems and expansion into new global markets. Users can track the company's progress through major clinical study publications and regulatory milestone achievements.
Bookmark this page for structured access to InspireMD's latest verified news. Check regularly for updates on carotid stenting advancements, financial disclosures, and evidence-based medical device innovations shaping stroke prevention care.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its first quarter 2025 financial results release for May 9, 2025.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via telephone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's website webcast.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, has announced the approval of inducement grants for 11 new non-executive employees. The grants, consisting of 299,398 shares of restricted stock, were approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The grants, dated April 1, 2025, were issued outside of InspireMD's 2021 Equity Compensation Plan and under the company's 2024 Inducement Plan. The restricted stock follows a three-year vesting schedule: one-third vests after the first year, with the remaining portions vesting equally on the second and third anniversaries, contingent on continued employment.
InspireMD (Nasdaq: NSPR), the developer of CGuard™ Prime carotid stent system for carotid artery disease treatment and stroke prevention, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The presentation is scheduled for Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. Investors and interested parties can access a live audio webcast of the presentation, with a replay available for 90 days through the company's website at inspiremd.com in the News & Events section.
InspireMD (NSPR) reported its Q4 and full-year 2024 financial results, highlighting record quarterly revenue of $1.95M and 3.5K units in served markets. The company achieved a 10.7% revenue increase in Q4 2024 compared to Q4 2023.
Key developments include the FDA engagement for CGuard Prime carotid stent system's PMA application, with anticipated approval in H1 2025. The company established its headquarters in Miami and initiated the CGUARDIANS II pivotal study for TCAR procedures.
Financial highlights: Full-year 2024 revenue increased 13% to $7.01M, though gross margin decreased to 21.5% from 29.1%. Q4 operating expenses rose 55.8% to $9.84M, primarily due to US personnel expansion and commercial preparation costs. The company ended 2024 with $34.64M in cash and marketable securities.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via phone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's investor relations website.
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for stroke prevention, announced that its Compensation Committee has approved inducement grants to six new non-executive employees totaling 138,442 shares of restricted stock.
These grants were made outside of InspireMD's 2021 Equity Compensation Plan with a grant date of February 5, 2025. The inducement plan is exclusively used for equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement for joining the company.
The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remainder vesting in two equal installments on the second and third anniversaries, contingent upon continued employment with InspireMD as of these vesting dates.
InspireMD (NSPR) and NAMSA announced their partnership for the CGUARDIANS II pivotal study of the CGuard Prime™ 80 cm carotid stent system for Transcarotid Artery Revascularization (TCAR) procedures. The study, which enrolled its first patient in December 2024, aims to evaluate the safety and effectiveness of the TCAR procedure using CGuard Prime with an FDA-authorized embolic protection device.
The prospective, multi-center, single-arm pivotal study targets a minimum enrollment of 50 evaluable patients at high risk for adverse events from carotid endarterectomy. With over 30,000 TCAR procedures performed annually in the U.S., this represents a significant market expansion opportunity for InspireMD's carotid stenting solutions.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, announced that its Compensation Committee has approved inducement grants for a new non-executive employee. The grant consists of 18,000 shares of restricted stock, issued outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.
The restricted stock will vest over three years, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent upon continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is specifically designed for new employees or those returning after a bona fide period of non-employment.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, has announced inducement grants for nine new non-executive employees. The Compensation Committee approved a total of 372,135 shares of restricted stock outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.
The restricted stock grants are structured with a three-year vesting period: one-third vests after the first year, with the remaining shares vesting equally on the second and third anniversaries of the grant date. These grants, made under Nasdaq Listing Rule 5635(c)(4), are specifically designed as employment inducements for new hires who were not previously InspireMD employees.
InspireMD (NSPR) announced that Chief Financial Officer Craig Shore will retire after 15 years with the company. Shore will remain in his position until a successor is appointed and will assist in the transition. The announcement comes as the company anticipates potential FDA approval in the first half of 2025 for its CGuard™ Embolic Prevention Stent System.
CEO Marvin Slosman praised Shore's commitment to building the company's position as a global leader in carotid interventions. Shore expressed confidence in the company's future growth trajectory and its leadership in carotid intervention and stroke prevention. The company has initiated a search for a new CFO.
